Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1Gastrointestinal 1

Conditions

Pancreatic Neoplasms 1Metastatic NUT Carcinoma 1Lymphoma, T-Cell 1Lymphoma, B-Cell 1Lymphoma 1

Interventions

Rituximab 4ibrutinib 2fludarabine phosphate 2fludarabine 2blinatumomab 2Vorinostat 2Radiation 2Nivolumab 2Lenalidomide 2Gemcitabine 2Cytarabine 2Cyclophosphamide 2CT-P10 2umbralisib 1ublituximab 1tafasitamab 1polatuzumab vedotin 1pembrolizumab 1ofatumumab 1molibresib 1magrolimab 1iberdomide 1glofitamab 1entinostat 1cirmtuzumab 1carmustine, poliferprosan 20 drug combination 1asparaginase erwinia chrysanthemi recombinant 1X-Rays 1Tacrolimus 1Stem Cell Transplantation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Lymphoma, B-Cell × molibresib × Clear all
NCT03925428 2020-09-28

Testing a New Anti-cancer Drug Combination, Entinostat and GSK525762C, for Advanced and Refractory Solid Tumors and Lymphomas

National Cancer Institute (NCI)

Phase 1 Withdrawn
GastrointestinalLymphoid

Lymphoma, Pancreatic Neoplasms, Lymphoma, B-Cell, Lymphoma, T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡